Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
IPXL's Cash to Debt is ranked higher than
96% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. IPXL: No Debt )
IPXL' s 10-Year Cash to Debt Range
Min: 0.68   Max: No Debt
Current: No Debt

Equity to Asset 0.81
IPXL's Equity to Asset is ranked higher than
86% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. IPXL: 0.81 )
IPXL' s 10-Year Equity to Asset Range
Min: 0.2   Max: 0.84
Current: 0.81

0.2
0.84
F-Score: 6
Z-Score: 8.64
M-Score: -2.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 12.63
IPXL's Operating margin (%) is ranked higher than
80% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. IPXL: 12.63 )
IPXL' s 10-Year Operating margin (%) Range
Min: -1418.74   Max: 44.72
Current: 12.63

-1418.74
44.72
Net-margin (%) 8.42
IPXL's Net-margin (%) is ranked higher than
78% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. IPXL: 8.42 )
IPXL' s 10-Year Net-margin (%) Range
Min: -1376.35   Max: 46
Current: 8.42

-1376.35
46
ROE (%) 5.65
IPXL's ROE (%) is ranked higher than
72% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. IPXL: 5.65 )
IPXL' s 10-Year ROE (%) Range
Min: -341.31   Max: 125.75
Current: 5.65

-341.31
125.75
ROA (%) 4.63
IPXL's ROA (%) is ranked higher than
77% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. IPXL: 4.63 )
IPXL' s 10-Year ROA (%) Range
Min: -70.9   Max: 38.8
Current: 4.63

-70.9
38.8
ROC (Joel Greenblatt) (%) 22.81
IPXL's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. IPXL: 22.81 )
IPXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -297.18   Max: 235.82
Current: 22.81

-297.18
235.82
Revenue Growth (3Y)(%) -17.80
IPXL's Revenue Growth (3Y)(%) is ranked higher than
53% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. IPXL: -17.80 )
IPXL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 203.4
Current: -17.8

0
203.4
EBITDA Growth (3Y)(%) -24.50
IPXL's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. IPXL: -24.50 )
IPXL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 61.6
Current: -24.5

0
61.6
EPS Growth (3Y)(%) -27.30
IPXL's EPS Growth (3Y)(%) is ranked higher than
58% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. IPXL: -27.30 )
IPXL' s 10-Year EPS Growth (3Y)(%) Range
Min: -32.2   Max: 55.1
Current: -27.3

-32.2
55.1
» IPXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

IPXL Guru Trades in Q4 2013

Paul Tudor Jones 11,100 sh (New)
Jim Simons 1,408,300 sh (+32.21%)
RS Investment Management 2,350,484 sh (-7.28%)
Steven Cohen 17,474 sh (-90.16%)
» More
Q1 2014

IPXL Guru Trades in Q1 2014

John Hussman 220,000 sh (New)
Steven Cohen 63,998 sh (+266.25%)
Paul Tudor Jones 18,000 sh (+62.16%)
Jim Simons 1,046,000 sh (-25.73%)
RS Investment Management 1,328,437 sh (-43.48%)
» More
Q2 2014

IPXL Guru Trades in Q2 2014

NWQ Managers 984,841 sh (New)
John Hussman 310,000 sh (+40.91%)
Paul Tudor Jones 18,000 sh (unchged)
Jim Simons Sold Out
RS Investment Management 940,950 sh (-29.17%)
» More
Q3 2014

IPXL Guru Trades in Q3 2014

Jim Simons 39,400 sh (New)
Joel Greenblatt 33,709 sh (New)
Paul Tudor Jones 36,853 sh (+104.74%)
NWQ Managers 1,298,995 sh (+31.9%)
RS Investment Management 809,959 sh (-13.92%)
John Hussman 250,000 sh (-19.35%)
» More
» Details

Insider Trades

Latest Guru Trades with IPXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-09-30 Reduce -19.35%0.14%$22.77 - $30.68 $ 31.3223%250000
NWQ Managers 2014-09-30 Add 31.9%0.08%$22.77 - $30.68 $ 31.3223%1298995
Joel Greenblatt 2014-09-30 New Buy0.01%$22.77 - $30.68 $ 31.3223%33709
NWQ Managers 2014-06-30 New Buy0.3%$23.6 - $30.68 $ 31.3216%984841
John Hussman 2014-06-30 Add 40.91%0.21%$23.6 - $30.68 $ 31.3216%310000
John Hussman 2014-03-31 New Buy0.44%$22.02 - $27.91 $ 31.3226%220000
John Hussman 2012-03-31 Sold Out 0.11%$18.64 - $24.37 $ 31.3251%0
Joel Greenblatt 2012-03-31 Sold Out 0.05%$18.64 - $24.37 $ 31.3251%0
Joel Greenblatt 2011-12-31 Reduce -88.51%0.47%$16.53 - $20.75 $ 31.3268%21057
Joel Greenblatt 2011-09-30 Reduce -40.22%0.38%$15.26 - $21.56 $ 31.3260%183187
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 47.30
IPXL's P/E(ttm) is ranked higher than
75% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.60 vs. IPXL: 47.30 )
IPXL' s 10-Year P/E(ttm) Range
Min: 4.04   Max: 1043
Current: 47.3

4.04
1043
P/B 2.50
IPXL's P/B is ranked higher than
77% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. IPXL: 2.50 )
IPXL' s 10-Year P/B Range
Min: 1.32   Max: 18.07
Current: 2.5

1.32
18.07
P/S 3.90
IPXL's P/S is ranked higher than
72% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. IPXL: 3.90 )
IPXL' s 10-Year P/S Range
Min: 1.17   Max: 19.49
Current: 3.9

1.17
19.49
EV-to-EBIT 25.09
IPXL's EV-to-EBIT is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. IPXL: 25.09 )
IPXL' s 10-Year EV-to-EBIT Range
Min: -1981.9   Max: 628.6
Current: 25.09

-1981.9
628.6
PEG 11.41
IPXL's PEG is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPXL: 11.41 )
IPXL' s 10-Year PEG Range
Min: 0.18   Max: 307.84
Current: 11.41

0.18
307.84
Shiller P/E 19.30
IPXL's Shiller P/E is ranked higher than
92% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.36 vs. IPXL: 19.30 )
IPXL' s 10-Year Shiller P/E Range
Min: 10.16   Max: 61.99
Current: 19.3

10.16
61.99
Current Ratio 4.41
IPXL's Current Ratio is ranked higher than
83% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. IPXL: 4.41 )
IPXL' s 10-Year Current Ratio Range
Min: 1.12   Max: 10.65
Current: 4.41

1.12
10.65
Quick Ratio 3.91
IPXL's Quick Ratio is ranked higher than
84% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. IPXL: 3.91 )
IPXL' s 10-Year Quick Ratio Range
Min: 0.63   Max: 10.07
Current: 3.91

0.63
10.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.30
IPXL's Price/Net Cash is ranked higher than
92% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPXL: 9.30 )
IPXL' s 10-Year Price/Net Cash Range
Min: 5.39   Max: 436.33
Current: 9.3

5.39
436.33
Price/Net Current Asset Value 5.60
IPXL's Price/Net Current Asset Value is ranked higher than
92% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. IPXL: 5.60 )
IPXL' s 10-Year Price/Net Current Asset Value Range
Min: 3.66   Max: 368.75
Current: 5.6

3.66
368.75
Price/Tangible Book 2.70
IPXL's Price/Tangible Book is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.32 vs. IPXL: 2.70 )
IPXL' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 26.35
Current: 2.7

1.45
26.35
Price/DCF (Projected) 2.00
IPXL's Price/DCF (Projected) is ranked higher than
88% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. IPXL: 2.00 )
IPXL' s 10-Year Price/DCF (Projected) Range
Min: 1   Max: 3.82
Current: 2

1
3.82
Price/Median PS Value 1.20
IPXL's Price/Median PS Value is ranked higher than
72% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. IPXL: 1.20 )
IPXL' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 26.88
Current: 1.2

0.42
26.88
Price/Graham Number 2.30
IPXL's Price/Graham Number is ranked higher than
85% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.17 vs. IPXL: 2.30 )
IPXL' s 10-Year Price/Graham Number Range
Min: 0.68   Max: 31.77
Current: 2.3

0.68
31.77
Earnings Yield (Greenblatt) 4.00
IPXL's Earnings Yield (Greenblatt) is ranked higher than
81% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. IPXL: 4.00 )
IPXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 55.9
Current: 4

0.2
55.9
Forward Rate of Return (Yacktman) -18.20
IPXL's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.85 vs. IPXL: -18.20 )
IPXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.3   Max: 60
Current: -18.2

-18.3
60

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:ILR.Germany,
Impax Laboratories, Inc., is a Delaware corporation was incorporated in 1995. It is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as 'generics' in addition to the development and marketing of branded products. The Company operates in two segments namely Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Division develops, manufactures, sells and distributes its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Company develops, manufacture, sell and distribute specialty generic pharmaceuticals. The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products mainly through four sales channels: the 'Global products' sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the 'Private Label' sales channel, for generic pharmaceutical over-the-counter ('OTC') and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the 'Rx Partner' sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements; and the 'OTC Partner' sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Impax Division is engaged in the development of proprietary brand pharmaceutical products. The Impax Division is also engaged in the sale and distribution of branded Zomig(r) (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (AZ Agreement) with AstraZeneca UK Limited (AstraZeneca). The Company's Impax Division develops proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system ('CNS') disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. The Company markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The chemical raw materials, essential to its business, are generally readily available from multiple sources in the U.S. and throughout the world. Generic pharmaceutical product deve
» More Articles for IPXL

Headlines

Articles On GuruFocus.com
comment on IPXL Sep 24 2012 
President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010 
Impax Laboratories Reports Second Quarter 2009 Financial Results Aug 04 2009 

More From Our Partners
Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst Blog Dec 16 2014 - ZACKS

More From Other Websites
Impax Laboratories, Inc. -- Moody's Assigns B1 CFR to Impax; Stable Outlook Dec 03 2014
IMPAX LABORATORIES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Dec 02 2014
Is Impax Laboratories (IPXL) Stock a Solid Choice Right Now? Nov 28 2014
Corium International (CORI) Jumps: Stock Moves 14.3% Higher Nov 19 2014
IMPAX LABORATORIES INC Financials Nov 14 2014
Mallinckrodt ADHD Drug Hits FDA Trouble; Stock Drops Nov 13 2014
Impax Laboratories to Present at the 2014 Credit Suisse Healthcare Conference on November 11 Nov 10 2014
Impax Laboratories to Present at the 2014 Credit Suisse Healthcare Conference on November 11 Nov 10 2014
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session Nov 10 2014
IMPAX LABORATORIES INC Files SEC form 8-K, Other Events Nov 07 2014
10-Q for Impax Laboratories, Inc. Nov 06 2014
Impax Submits Marketing Authorization Application to EMA for IPX066 (Carbidopa-Levodopa)... Nov 06 2014
Impax Submits Marketing Authorization Application to EMA for IPX066 (Carbidopa-Levodopa)... Nov 06 2014
Impax Labs misses 3Q profit forecasts Nov 04 2014
Impax Labs misses 3Q profit forecasts Nov 04 2014
IMPAX LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 04 2014
Impax's Third Quarter 2014 Revenues Increased 19% to $158 Million Nov 04 2014
Q3 2014 Impax Laboratories Inc Earnings Release - Before Market Open Nov 04 2014
Impax's Third Quarter 2014 Revenues Increased 19% to $158 Million Nov 04 2014
IPXL Shareholder Alert: Do You Own Stock in IMPAX Laboratories Inc.? Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK